Project 170936

Cardiovascular pharmacology of the B1 and B2 receptors for kinins

170936

Cardiovascular pharmacology of the B1 and B2 receptors for kinins

$663,985
Project Information
Study Type: Other Mechanistic_Study
Therapeutic Area: Cancer
Research Theme: Biomedical
Disease Area: Fanconi anemia, cancer
Data Type: Canadian
Institution & Funding
Principal Investigator(s): Marceau, François
Co-Investigator(s): Adam, Albert
Institution: Centre hospitalier de l'Université Laval (Québec)
CIHR Institute: Circulatory and Respiratory Health
Program: Operating Grant
Peer Review Committee: Cardiovascular System - C: Vascular System
Competition Year: 2008
Term: 5 yrs 0 mth
Abstract Summary

The kinins are hormone-like substances generated from blood, but also potentially from the cells that constitute the blood vessels. Two types of receptors are activated by kinins: the B2 receptors are preformed and widely distributed. The B1 receptors are not present in healthy tissues, but ther expression is completely induced under inflammatory or tissue injury conditions. Angiotensin converting enzyme (ACE) inhibitors are a widely used class of drugs used for hypertension and other cardiovascular/renal ailments that inteact with kinins, because ACE is a prominent kinin-destroying enzyme in vivo. Thus, a part of the therapeutic and/or side effects of ACE inhibitors may derive from an increased kinin concentration in tissues, vascular responses such as vasodilation and increased permeability and adaptative changes in the population of kinin receptors receptors. Objective of the project: (1) To verify whether a particular blood vessel cell type, the endothelial cell, can produce kinin precursors and process them, thus leading to the autostimulation of cell functions under ACE blockade. (2) To verify the relative importance of kinin inactivation mechanisms in human endothelial cells (ACE being one of them). (3) To establish in endothelial cell culture and in live animals (rabbits) how a widely used anti-hypertensive drug class, the ACE inhibitors, or inflammation change the kinin receptor populations (increase in the B1 type, decrease in B2 receptors). This may be related to a rare but dangerous side effect of ACE inhibitors, angioedema, because there are theoretical reasons to believe that it is linked to B1 receptor expression. Significance: The role of the B1 receptors has only been rarely addressed in the analysis of the actions of ACE inhibitors. The applicants have developed over the years many experimental approaches related to the kinin receptors an exploit an analytical platform (immunoreactive kinin determination) unique in the world.

Research Characteristics

This project includes the following research characteristics:

Regulatory Pathway
Knowledge Translation Focus
Biomarker Endpoints
Rare Disease
Study Justification

"Our research program is focused on how cells respond to DNA damage, specifically DNA interstrand crosslinks."

Novelty Statement

"The ultimate goal of this research is to contribute to a better understanding of how the loss of tissue architecture contributes to cancer, and to identify new avenues for therapeutic intervention."

Methodology Innovation

studying DNA interstrand crosslink repair pathways to understand cancer etiology and treatment

Keywords
Analytical Biochemistry Bradykinin Receptors Cardiovascular Pharmacology Radioligand Studies Vascular Permeability